These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8736497)

  • 1. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody.
    Holliger P; Brissinck J; Williams RL; Thielemans K; Winter G
    Protein Eng; 1996 Mar; 9(3):299-305. PubMed ID: 8736497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
    Kipriyanov SM; Moldenhauer G; Strauss G; Little M
    Int J Cancer; 1998 Aug; 77(5):763-72. PubMed ID: 9688311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris.
    FitzGerald K; Holliger P; Winter G
    Protein Eng; 1997 Oct; 10(10):1221-5. PubMed ID: 9488147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and characterization of bispecific single-chain antibody fragments.
    De Jonge J; Brissinck J; Heirman C; Demanet C; Leo O; Moser M; Thielemans K
    Mol Immunol; 1995 Dec; 32(17-18):1405-12. PubMed ID: 8643110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
    Le Gall F; Reusch U; Little M; Kipriyanov SM
    Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas.
    Helfrich W; Kroesen BJ; Roovers RC; Westers L; Molema G; Hoogenboom HR; de Leij L
    Int J Cancer; 1998 Apr; 76(2):232-9. PubMed ID: 9537586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes.
    Korn T; Müller R; Kontermann RE
    J Immunother; 2004; 27(2):99-106. PubMed ID: 14770081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.
    Wei L; Dongmei F; Ming Y; Ruizan S; Yan Y; Linlin J; Cihui Y; Shuangjing L; Min W; Jianxiang W; Dongsheng X
    Cell Oncol (Dordr); 2012 Dec; 35(6):423-34. PubMed ID: 23055339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL.
    Jost CR; Titus JA; Kurucz I; Segal DM
    Mol Immunol; 1996 Feb; 33(2):211-9. PubMed ID: 8649442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
    Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
    Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
    Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
    J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
    Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
    Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
    Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
    J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.